Transforming Ideas Into Treatments
Our passion for patients in need fuels our dedication to fill the therapeutic void with potential for the future. With RNA as the basis of our discovery platform, we are able to bring therapeutic options to patients who otherwise would have limited or no options.
Ionis has discovered and developed marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiometabolic diseases.
For more information about DAWNZERA® and U.S. prescribing information, visit DAWNZERA.com.
For more information about TRYNGOLZA® and U.S. prescribing information, visit TRYNGOLZA.com.
For more information about ZANVASTROTM and U.S. prescribing information, visit ZANVASTRO.com.
HIBSAGOTM is marketed by GSK. For more information about HIBSAGO and U.S. prescribing information, visit HIBSAGO.com.
QALSODY® is marketed by Biogen. For more information about QALSODY and U.S. prescribing information, visit QALSODY.com.
SPINRAZA® is marketed by Biogen. For more information about SPINRAZA and U.S. prescribing information, visit SPINRAZA.com.
WAINUA™ is marketed by AstraZeneca. For more information about WAINUA and U.S. prescribing information, visit WAINUA.com.
US-ABR-2400001 v8 11/2026